Premarket Mover: Lineage Cell Therapeutics Inc (LCTX) Up 3.05%

Lineage Cell Therapeutics Inc (LCTX) has gained Monday morning, with the stock rising 3.05% in pre-market trading to 1.69. LCTX's short-term technical score of 31 indicates that the stock has traded less bullishly over the last month than 69% of stocks on the market. In the Biotechnology industry, which ranks 75 out of 146 industries, the stock ranks higher than 22% of stocks. Lineage Cell Therapeutics Inc has risen 4.46% over the past month, closing at $1.69 on July 4. During this period of time, the stock fell as low as $1.57 and as high as $1.76. LCTX has an average analyst recommendation of Strong Buy. The company has an average price target of $6.00.

LCTX has an Overall Score of 69. Find out what this means to you and get the rest of the rankings on LCTX!

See Full LCTX Report

Lineage Cell Therapeutics Inc has a Long-Term Technical rank of 92. This means that trading over the last 200 trading days has placed the company in the upper half of stocks with 8% of the market scoring higher. In the Biotechnology industry which is number 106 by this metric, LCTX ranks better than 106% of stocks.

Important Dates for Investors in LCTX:

-Lineage Cell Therapeutics Inc is set to release earnings on 8/11/2022. Over the last 12 months, the company has reported EPS of $-0.29. -We do not have a set dividend date for Lineage Cell Therapeutics Inc at this time. Click Here To Get The Full Report on Lineage Cell Therapeutics Inc (LCTX)